MGRO — MustGrow Biologics Income Statement
0.000.00%
Last trade - 00:00- CA$55.77m
- CA$53.29m
- CA$0.40m
Annual income statement for MustGrow Biologics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.013 | 0.006 | 4.71 | 0.398 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 0.301 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 3.26 | 3.02 | 5.69 | 5.52 | 5.51 |
| Operating Profit | -3.26 | -3.01 | -5.69 | -0.805 | -5.11 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -3.31 | -3.06 | -5.57 | -0.677 | -4.89 |
| Net Income After Taxes | -3.31 | -3.06 | -5.57 | -0.677 | -4.89 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.31 | -3.06 | -5.57 | -0.677 | -4.89 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.31 | -3.06 | -5.57 | -0.677 | -4.89 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.092 | -0.07 | -0.114 | -0.014 | -0.095 |